medigraphic.com
Colegio de Medicina Interna de México.

2019, Number 5

<< Back Next >>

Med Int Mex 2019; 35 (5)

Metabolic side effects of second-generation antipsychotics

Flores-Rojas LE, González-Zúñiga HLA

Language: Spanish
References: 36
Page: 721-731
PDF size: 437.87 Kb.


ABSTRACT

Antipsychotics are widely prescribed to treat a large number of neuropsychiatric problems. Antipsychotics are divided in two classes according to their chemical structure, typical or first generation and the atypical or second generation. The second-generation antipsychotics have greater benefits because they produce less extrapyramidal side effects; however, several studies in both humans and animals have related their administration to metabolic side effects, such as obesity, weight gain, diabetes, dyslipidemia, metabolic syndrome and insulin resistance. Because of the effects, clinical guidelines for the control and monitoring of patients with a treatment with these drugs have been established. The aim of this paper is to review some metabolic side effects produced by the second-generation antipsychotics and its possible mechanism of action, as well as the metabolic control or monitoring that patients treated with these drugs should have. The research of the articles was made in the databases: PubMed, EBSCOHOST, DynaMed and IntraMed.


REFERENCES

  1. Rang H, Dale M, Ritta J, Mcare P. Farmacología. 5ª ed. España: Elsevier; 2004.

  2. Aristil Chér P. M. Manual de Farmacología Básica y Clínica. 5ª ed. México: Mc Graw Hill; 2010.

  3. Salín Pascual R. Neurobioquímica y farmacología de los antipsicóticos atípicos. Rev Mex Neuroci 2005;6(6):500-507.

  4. Flórez J. Fármacos antipsicóticos neurolépticos. En: Armijo J, director. Farmacología Humana. 5ª ed. España: Elsevier; 2008:629-644.

  5. Company Plomer M. El uso de antipsicóticos de segunda generación en pacientes con esquizofrenia en edad adulta. ¿Modifica la morbimortalidad por enfermedad cardiovascular en comparación con los antipsicóticos de primera generación? Universitat de les Iles Balears 2016;4-7.

  6. Vogel M, Leon F, Torres R y Crossley N. Antipsicóticos de primera y segunda generación en esquizofrenia: eficacia, efectividad y efecto de la dosis utilizada. Rev Ciencias Médicas 2017;42(1):41-48. DOI: http://dx.doi.org/10.11565/ arsmed.v42i1.452.

  7. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists and North American Association for the Study Of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care Feb 2004;27(2):596-601. https://doi.org/10.2337/ diacare.27.2.596.

  8. Llorente M and Urrutia V. Diabetes, Psychiatric disorders, and the metabolic effects of antipsychotic medications. Clinical Diabetes 2006;24(1):18-24. https://doi.org/10.2337/ diaclin.24.1.18.

  9. Marazziti D, Piccini A, Dell’Osso L y col. Tendencias actuales en el tratamiento con antipsicóticos. Intramed. Abr 2017;23(21):2204-2216.

  10. Jurgën Möller H. Los efectos antipsicóticos y antidepresivos de los antipsicóticos de segunda generación. ¿Dos mecanismos farmacológicos diferentes? RET Revista de Toxicomanías 2005;44:3-14.

  11. Alp Ü, Wolfgang G. Side effects of atypical antipsychotics: a brief overview. World Psychiatry Jan 2008;7(1):58-62.

  12. Citromea L, Vreeland B. Obesity and mental illness. Mod Trends Pharmacopsychiatry 2009;26:25-46.

  13. Cortes Morales B. Síndrome metabólico y antipsicóticos de segunda generación. Rev Asoc Esp Neuropsiq 2011;31(110):303-320. http://dx.doi.org/10.4321/S0211- 57352011000200009.

  14. Shi L, Ascher-Svanum H, Chiang Y, Zhao Y, Fonseca V, Winstead D. Predictors of metabolic monitoring among schizophrenia patients with a new episode of secondgeneration antipsychotic use in the Veterans Health Administration. BMC Psychiatry. 2009 Dec 18;9:80. doi: 10.1186/1471-244X-9-80.

  15. Morrato E, Newcomer J, Allen R and Valuck R. Prevalence of baseline serum glucose and lipid testing in users of secod-generatios antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J Clin Psychiatry Feb 2008;69(2):316-322.

  16. Nguyen D, Brakoulias V, Boyce P. An evaluation of monitoring practices in patients on second generation antipsychotics. Australas Psychiatry. Aug 2009;17(4):295-9. doi: 10.1080/10398560902842519.

  17. Meyer J, et al. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1. Schizophr Res August 2008;103(1-3):104-109. doi: 10.1016/j.schres.2008.04.023.

  18. Schooler NR, Marder SR, Chengappa KN, Petrides G, Ames D, Wirshing WC, et al. Clozapine and risperidone in moderalitely refractory schizophrenia: a 6 month randomized dpuble-blind comparison. J Clin Psych 2016;77(5):628-34.

  19. Oviedo G, Gómez C, Bohórquez A, García J y col. Evaluación y seguimiento metabólico del paciente con diagnóstico de esquizofrenia. Rev Colombiana de Psiquiatría 2015;44(4):220-229. DOI: 10.1016/j.rcp.2015.05.008

  20. Barnett M, VonMuenster S, Wehring H, Popish S, McDonald K, et al. Assessment of monitoring for glucose and lipid dysregulation in adult Medi-Cal patients newly started on antipsychotics. Ann Clin Psychiat Feb 2010;22(1):9-18.

  21. Coccurello R, Caprioli A, Conti R, Ghirardi O, Borsini F, Carminati P, Moles A. Olanzapine (LY170053, 2-methyl-4- (4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine), but not the novel atypical antipsychotic ST2472 (9-piperazin-1-ylpyrrolo[2,1-b][1,3]benzothiazepine), chronic administration induces weigh gain, hyperphagia, and metabolic dysregulation in mice. J Pharmacol Exp Ther June 2008;326(3):905-911. doi: 10.1124/jpet.108.137240.

  22. Essock SM, Covell NH, Jackson CT. Antipsychotic drugs and schizophrenia. N Engl J Med 2006;19;354(3):298-300.

  23. Seeman M. Secondary effects of antipsychotics: women at greater risk than men. Schizophrenia Bulletin 2009;35(5):937-948. doi: 10.1093/schbul/sbn023.

  24. Dwyer D, Lu X-H and Bradley R. Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. Brain Res May 2003;971(1): 31-39. DOI: 10.1016/ s0006-8993(03)02351-5.

  25. Martins P, Haas M, Obici S. Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes Oct 2010; 59:2418-2425. doi: 10.2337/db10-0449.

  26. Houseknecht K, Robertson A, Zavadoski W, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007;32:289-297. DOI: 10.1038/sj.npp.1301209.

  27. Meyer J, Stahl S. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand Jan 2009;119(1):4-14. doi: 10.1111/j.1600-0447.2008.01317.x.

  28. Jano E, Johnson M, Chen H, et al. Determinants of atypical antipsychotic user in community-dwelling,1996-2004. Curr Med Res Opin 2008;24(3):709-16.

  29. Newcomer J. Metabolic syndrome and mental illness. Am J Manag Care Nov 2007;13(7):S170-S177.

  30. Morrato E, Newcomer J, Kamat S, Baser O, Harnett J, Mcuffel B. Metabolic screening after the American Diabetes Association’s consensus statement on antipsychotic drugs and diabetes. Diabetes Care June 2009;32(6):1037-1042. doi: 10.2337/dc08-1720.

  31. Stahl S, Mignon L, Meyer J. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand. Mar 2009;119(3):171-9. doi: 10.1111/j.1600- 0447.2008.01334.x.

  32. Yang LH, Chen TM, Yu ST, Chen YH. Olanzapina induces SREBP | related adipogenesis in 3T3-Li cells. Pharmacol Res 2007;56(3)202-8.

  33. Ader M, Kim S, Catalano K, Ionut V, Hucking K, Richey J, Kabir M, Bergman R. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease. A placebo controlled study of olanzapine and risperidone in dogs. Diabetes. March 2005;54:862-871. DOI: 10.2337/ diabetes.54.3.862.

  34. Obici S, Martins PJF. The role of brain in glucose metabolism. In: Principles of Diabetes Mellitus. Poretsky L, editor. Nueva York: Springer, 2010;89-104.

  35. Konner A, Janoschek R, Plum L, Jordan S, Rother E, Ma X, Xu C, Enriori P, Hampel B, Barsh G, Kahn C, Cowley M, Ashcroft F, Bruning JC. Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production. Cell Metab June 2007;5:438-449. DOI: 10.1016/j. cmet.2007.05.004.

  36. Morrato E, Druss B, Hartung D, Valuck R, Allen R, Campagna E, Newcomer J. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010;67(1):17-24. doi: 10.1001/ archgenpsychiatry.2009.179.




2020     |     www.medigraphic.com